InvestorsHub Logo
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Tuesday, 07/14/2009 7:12:43 AM

Tuesday, July 14, 2009 7:12:43 AM

Post# of 12450
US approval in 4Q 2009 ??

http://reports.finance.yahoo.com/w0?r=45713429:2

Developments Intelgenx announced that the FDA has finished its preliminary review and accepted Intelgenx’s NDA filing for CPI-300, a 450mg extended release Bupropion tablet. Impact Positive. Intelgenx is keeping to its timeline and we should see the tablet approved by Q4/09 and on the market by Q1/10. Comments The FDA has begun its full review of Intelgenx’s 450mg Bupropion tablet, which is excellent news for the company and maintains their timeline.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News